January 11, 2021 07:00 AM ESTUpdated 07:34 AM

GlaxoSmithKline backs a preclinical acne treatment from Eligo Bioscience that uses CRISPR to kill bacteria

Max Gelman

Senior Editor

Roughly three and a half years since bagging a $20 million financing round to develop its CRISPR-based microbiome modulation platform, Eligo Bioscience has made …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GlaxoSmithKline backs a preclinical acne treatment from Eligo Bioscience that uses CRISPR to kill bacteria

Max Gelman

Senior Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future

Glax­o­SmithK­line backs a pre­clin­i­cal ac­ne treat­ment from Eli­go Bio­science that us­es CRISPR to kill bac­te­ria

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

GlaxoSmithKline backs a preclinical acne treatment from Eligo Bioscience that uses CRISPR to kill bacteria

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

Exclusive: Florida cancer biotech raises $100M Series A

CMS explains what went into its first round of drug price negotiations

FDA approves Lilly's Zepbound for sleep apnea, likely cracking open Medicare market

Inside Isomorphic Labs: Demis Hassabis’ lab-free vision for biotech’s AI future